Long‐term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow‐up
Objective This study was undertaken to evaluate the long‐term efficacy, retention, and tolerability of add‐on brivaracetam (BRV) in clinical practice. Methods A multicenter, retrospective cohort study recruited all patients who initiated BRV between February and November 2016, with observation until...
Gespeichert in:
Veröffentlicht in: | Epilepsia (Copenhagen) 2021-12, Vol.62 (12), p.2994-3004 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3004 |
---|---|
container_issue | 12 |
container_start_page | 2994 |
container_title | Epilepsia (Copenhagen) |
container_volume | 62 |
creator | Strzelczyk, Adam Zaveta, Clara Podewils, Felix Möddel, Gabriel Langenbruch, Lisa Kovac, Stjepana Mann, Catrin Willems, Laurent M. Schulz, Juliane Fiedler, Barbara Kurlemann, Gerhard Schubert‐Bast, Susanne Rosenow, Felix Beuchat, Isabelle |
description | Objective
This study was undertaken to evaluate the long‐term efficacy, retention, and tolerability of add‐on brivaracetam (BRV) in clinical practice.
Methods
A multicenter, retrospective cohort study recruited all patients who initiated BRV between February and November 2016, with observation until February 2021.
Results
Long‐term data for 262 patients (mean age = 40 years, range = 5–81 years, 129 men) were analyzed, including 227 (87%) diagnosed with focal epilepsy, 19 (7%) with genetic generalized epilepsy, and 16 (6%) with other or unclassified epilepsy syndromes. Only 26 (10%) patients had never received levetiracetam (LEV), whereas 133 (50.8%) were switched from LEV. The length of BRV exposure ranged from 1 day to 5 years, with a median retention time of 1.6 years, resulting in a total BRV exposure time of 6829 months (569 years). The retention rate was 61.1% at 12 months, with a reported efficacy of 33.1% (79/239; 50% responder rate, 23 patients lost‐to‐follow‐up), including 10.9% reported as seizure‐free. The retention rate for the entire study period was 50.8%, and at last follow‐up, 133 patients were receiving BRV at a mean dose of 222 ± 104 mg (median = 200, range = 25–400), including 52 (39.1%) who exceeded the recommended upper dose of 200 mg. Fewer concomitant antiseizure medications and switching from LEV to BRV correlated with better short‐term responses, but no investigated parameters correlated with positive long‐term outcomes. BRV was discontinued in 63 (24%) patients due to insufficient efficacy, in 29 (11%) for psychobehavioral adverse events, in 25 (10%) for other adverse events, and in 24 (9%) for other reasons.
Significance
BRV showed a clinically useful 50% responder rate of 33% at 12 months and overall retention of >50%, despite 90% of included patients having previous LEV exposure. BRV was well tolerated; however, psychobehavioral adverse events occurred in one out of 10 patients. Although we identified short‐term response and retention predictors, we could not identify significant predictors for long‐term outcomes. |
doi_str_mv | 10.1111/epi.17087 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2579380324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2579380324</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3887-8a245b843700b48bdf7aacd503a0a2d66cd15fd7d74265f2a743197651a47a23</originalsourceid><addsrcrecordid>eNp1kU9u1DAUhy0EosPAggsgS2xAIq0dJ7aHXVUVqDQSLLqPXvwHXDlxsJ2OsuMIHKCLnoWjcBJcUlgg4Y1l-9P3nt8PoeeUHNOyTszkjqkgUjxAG9rWsqKUi4doQwhl1a6V5Ag9SemKECK4YI_REWs4kbyWG3SzD-Pnn9--ZxMHbKx1CtTyBufgTYTeeZfLCUaNo8lmzC6MOFjcR3cNEZTJMGA34tKAN1NacI4G8lDAt_gU-6J2edZuBI-H2WenyouJOJXLBR9c_oLnqdTC7Y_bxUBMd24bvA-H0tI8PUWPLPhknt3vW3T57vzy7EO1__j-4ux0Xykmpagk1E3by4YJQvpG9toKAKVbwoBArTlXmrZWCy2amre2BtEwuhO8pdAIqNkWvVq1UwxfZ5NyN7ikjPcwmjCnrm7FjknC6qagL_9Br8Icy_8KxUnDV3CLXq-UiiGlaGw3RTdAXDpKurvEujKw7ndihX1xb5z7wei_5J-ICnCyAocy4-X_pu7808Wq_AWcjKRn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2604679380</pqid></control><display><type>article</type><title>Long‐term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow‐up</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Strzelczyk, Adam ; Zaveta, Clara ; Podewils, Felix ; Möddel, Gabriel ; Langenbruch, Lisa ; Kovac, Stjepana ; Mann, Catrin ; Willems, Laurent M. ; Schulz, Juliane ; Fiedler, Barbara ; Kurlemann, Gerhard ; Schubert‐Bast, Susanne ; Rosenow, Felix ; Beuchat, Isabelle</creator><creatorcontrib>Strzelczyk, Adam ; Zaveta, Clara ; Podewils, Felix ; Möddel, Gabriel ; Langenbruch, Lisa ; Kovac, Stjepana ; Mann, Catrin ; Willems, Laurent M. ; Schulz, Juliane ; Fiedler, Barbara ; Kurlemann, Gerhard ; Schubert‐Bast, Susanne ; Rosenow, Felix ; Beuchat, Isabelle</creatorcontrib><description>Objective
This study was undertaken to evaluate the long‐term efficacy, retention, and tolerability of add‐on brivaracetam (BRV) in clinical practice.
Methods
A multicenter, retrospective cohort study recruited all patients who initiated BRV between February and November 2016, with observation until February 2021.
Results
Long‐term data for 262 patients (mean age = 40 years, range = 5–81 years, 129 men) were analyzed, including 227 (87%) diagnosed with focal epilepsy, 19 (7%) with genetic generalized epilepsy, and 16 (6%) with other or unclassified epilepsy syndromes. Only 26 (10%) patients had never received levetiracetam (LEV), whereas 133 (50.8%) were switched from LEV. The length of BRV exposure ranged from 1 day to 5 years, with a median retention time of 1.6 years, resulting in a total BRV exposure time of 6829 months (569 years). The retention rate was 61.1% at 12 months, with a reported efficacy of 33.1% (79/239; 50% responder rate, 23 patients lost‐to‐follow‐up), including 10.9% reported as seizure‐free. The retention rate for the entire study period was 50.8%, and at last follow‐up, 133 patients were receiving BRV at a mean dose of 222 ± 104 mg (median = 200, range = 25–400), including 52 (39.1%) who exceeded the recommended upper dose of 200 mg. Fewer concomitant antiseizure medications and switching from LEV to BRV correlated with better short‐term responses, but no investigated parameters correlated with positive long‐term outcomes. BRV was discontinued in 63 (24%) patients due to insufficient efficacy, in 29 (11%) for psychobehavioral adverse events, in 25 (10%) for other adverse events, and in 24 (9%) for other reasons.
Significance
BRV showed a clinically useful 50% responder rate of 33% at 12 months and overall retention of >50%, despite 90% of included patients having previous LEV exposure. BRV was well tolerated; however, psychobehavioral adverse events occurred in one out of 10 patients. Although we identified short‐term response and retention predictors, we could not identify significant predictors for long‐term outcomes.</description><identifier>ISSN: 0013-9580</identifier><identifier>EISSN: 1528-1167</identifier><identifier>DOI: 10.1111/epi.17087</identifier><identifier>PMID: 34608628</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Adult ; Adverse events ; Aged ; Aged, 80 and over ; Anticonvulsants - adverse effects ; Child ; Child, Preschool ; Drug dosages ; Drug Therapy, Combination ; Epilepsy ; Epilepsy - chemically induced ; Epilepsy - drug therapy ; Etiracetam ; Female ; Follow-Up Studies ; Humans ; levetiracetam ; Levetiracetam - therapeutic use ; Male ; Middle Aged ; Patients ; Pyrrolidinones - adverse effects ; refractory ; Retention ; Retrospective Studies ; seizure ; Seizures ; SV2A ; Treatment Outcome ; Young Adult</subject><ispartof>Epilepsia (Copenhagen), 2021-12, Vol.62 (12), p.2994-3004</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC on behalf of International League Against Epilepsy</rights><rights>2021 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3887-8a245b843700b48bdf7aacd503a0a2d66cd15fd7d74265f2a743197651a47a23</citedby><cites>FETCH-LOGICAL-c3887-8a245b843700b48bdf7aacd503a0a2d66cd15fd7d74265f2a743197651a47a23</cites><orcidid>0000-0001-9745-7258 ; 0000-0002-9300-4443 ; 0000-0001-6288-9915 ; 0000-0003-1545-7364 ; 0000-0002-3989-7471 ; 0000-0001-8226-1674 ; 0000-0001-6663-2631</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fepi.17087$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fepi.17087$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34608628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Strzelczyk, Adam</creatorcontrib><creatorcontrib>Zaveta, Clara</creatorcontrib><creatorcontrib>Podewils, Felix</creatorcontrib><creatorcontrib>Möddel, Gabriel</creatorcontrib><creatorcontrib>Langenbruch, Lisa</creatorcontrib><creatorcontrib>Kovac, Stjepana</creatorcontrib><creatorcontrib>Mann, Catrin</creatorcontrib><creatorcontrib>Willems, Laurent M.</creatorcontrib><creatorcontrib>Schulz, Juliane</creatorcontrib><creatorcontrib>Fiedler, Barbara</creatorcontrib><creatorcontrib>Kurlemann, Gerhard</creatorcontrib><creatorcontrib>Schubert‐Bast, Susanne</creatorcontrib><creatorcontrib>Rosenow, Felix</creatorcontrib><creatorcontrib>Beuchat, Isabelle</creatorcontrib><title>Long‐term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow‐up</title><title>Epilepsia (Copenhagen)</title><addtitle>Epilepsia</addtitle><description>Objective
This study was undertaken to evaluate the long‐term efficacy, retention, and tolerability of add‐on brivaracetam (BRV) in clinical practice.
Methods
A multicenter, retrospective cohort study recruited all patients who initiated BRV between February and November 2016, with observation until February 2021.
Results
Long‐term data for 262 patients (mean age = 40 years, range = 5–81 years, 129 men) were analyzed, including 227 (87%) diagnosed with focal epilepsy, 19 (7%) with genetic generalized epilepsy, and 16 (6%) with other or unclassified epilepsy syndromes. Only 26 (10%) patients had never received levetiracetam (LEV), whereas 133 (50.8%) were switched from LEV. The length of BRV exposure ranged from 1 day to 5 years, with a median retention time of 1.6 years, resulting in a total BRV exposure time of 6829 months (569 years). The retention rate was 61.1% at 12 months, with a reported efficacy of 33.1% (79/239; 50% responder rate, 23 patients lost‐to‐follow‐up), including 10.9% reported as seizure‐free. The retention rate for the entire study period was 50.8%, and at last follow‐up, 133 patients were receiving BRV at a mean dose of 222 ± 104 mg (median = 200, range = 25–400), including 52 (39.1%) who exceeded the recommended upper dose of 200 mg. Fewer concomitant antiseizure medications and switching from LEV to BRV correlated with better short‐term responses, but no investigated parameters correlated with positive long‐term outcomes. BRV was discontinued in 63 (24%) patients due to insufficient efficacy, in 29 (11%) for psychobehavioral adverse events, in 25 (10%) for other adverse events, and in 24 (9%) for other reasons.
Significance
BRV showed a clinically useful 50% responder rate of 33% at 12 months and overall retention of >50%, despite 90% of included patients having previous LEV exposure. BRV was well tolerated; however, psychobehavioral adverse events occurred in one out of 10 patients. Although we identified short‐term response and retention predictors, we could not identify significant predictors for long‐term outcomes.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adverse events</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticonvulsants - adverse effects</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Drug dosages</subject><subject>Drug Therapy, Combination</subject><subject>Epilepsy</subject><subject>Epilepsy - chemically induced</subject><subject>Epilepsy - drug therapy</subject><subject>Etiracetam</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>levetiracetam</subject><subject>Levetiracetam - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Pyrrolidinones - adverse effects</subject><subject>refractory</subject><subject>Retention</subject><subject>Retrospective Studies</subject><subject>seizure</subject><subject>Seizures</subject><subject>SV2A</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0013-9580</issn><issn>1528-1167</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kU9u1DAUhy0EosPAggsgS2xAIq0dJ7aHXVUVqDQSLLqPXvwHXDlxsJ2OsuMIHKCLnoWjcBJcUlgg4Y1l-9P3nt8PoeeUHNOyTszkjqkgUjxAG9rWsqKUi4doQwhl1a6V5Ag9SemKECK4YI_REWs4kbyWG3SzD-Pnn9--ZxMHbKx1CtTyBufgTYTeeZfLCUaNo8lmzC6MOFjcR3cNEZTJMGA34tKAN1NacI4G8lDAt_gU-6J2edZuBI-H2WenyouJOJXLBR9c_oLnqdTC7Y_bxUBMd24bvA-H0tI8PUWPLPhknt3vW3T57vzy7EO1__j-4ux0Xykmpagk1E3by4YJQvpG9toKAKVbwoBArTlXmrZWCy2amre2BtEwuhO8pdAIqNkWvVq1UwxfZ5NyN7ikjPcwmjCnrm7FjknC6qagL_9Br8Icy_8KxUnDV3CLXq-UiiGlaGw3RTdAXDpKurvEujKw7ndihX1xb5z7wei_5J-ICnCyAocy4-X_pu7808Wq_AWcjKRn</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Strzelczyk, Adam</creator><creator>Zaveta, Clara</creator><creator>Podewils, Felix</creator><creator>Möddel, Gabriel</creator><creator>Langenbruch, Lisa</creator><creator>Kovac, Stjepana</creator><creator>Mann, Catrin</creator><creator>Willems, Laurent M.</creator><creator>Schulz, Juliane</creator><creator>Fiedler, Barbara</creator><creator>Kurlemann, Gerhard</creator><creator>Schubert‐Bast, Susanne</creator><creator>Rosenow, Felix</creator><creator>Beuchat, Isabelle</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9745-7258</orcidid><orcidid>https://orcid.org/0000-0002-9300-4443</orcidid><orcidid>https://orcid.org/0000-0001-6288-9915</orcidid><orcidid>https://orcid.org/0000-0003-1545-7364</orcidid><orcidid>https://orcid.org/0000-0002-3989-7471</orcidid><orcidid>https://orcid.org/0000-0001-8226-1674</orcidid><orcidid>https://orcid.org/0000-0001-6663-2631</orcidid></search><sort><creationdate>202112</creationdate><title>Long‐term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow‐up</title><author>Strzelczyk, Adam ; Zaveta, Clara ; Podewils, Felix ; Möddel, Gabriel ; Langenbruch, Lisa ; Kovac, Stjepana ; Mann, Catrin ; Willems, Laurent M. ; Schulz, Juliane ; Fiedler, Barbara ; Kurlemann, Gerhard ; Schubert‐Bast, Susanne ; Rosenow, Felix ; Beuchat, Isabelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3887-8a245b843700b48bdf7aacd503a0a2d66cd15fd7d74265f2a743197651a47a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adverse events</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticonvulsants - adverse effects</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Drug dosages</topic><topic>Drug Therapy, Combination</topic><topic>Epilepsy</topic><topic>Epilepsy - chemically induced</topic><topic>Epilepsy - drug therapy</topic><topic>Etiracetam</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>levetiracetam</topic><topic>Levetiracetam - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Pyrrolidinones - adverse effects</topic><topic>refractory</topic><topic>Retention</topic><topic>Retrospective Studies</topic><topic>seizure</topic><topic>Seizures</topic><topic>SV2A</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strzelczyk, Adam</creatorcontrib><creatorcontrib>Zaveta, Clara</creatorcontrib><creatorcontrib>Podewils, Felix</creatorcontrib><creatorcontrib>Möddel, Gabriel</creatorcontrib><creatorcontrib>Langenbruch, Lisa</creatorcontrib><creatorcontrib>Kovac, Stjepana</creatorcontrib><creatorcontrib>Mann, Catrin</creatorcontrib><creatorcontrib>Willems, Laurent M.</creatorcontrib><creatorcontrib>Schulz, Juliane</creatorcontrib><creatorcontrib>Fiedler, Barbara</creatorcontrib><creatorcontrib>Kurlemann, Gerhard</creatorcontrib><creatorcontrib>Schubert‐Bast, Susanne</creatorcontrib><creatorcontrib>Rosenow, Felix</creatorcontrib><creatorcontrib>Beuchat, Isabelle</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Epilepsia (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strzelczyk, Adam</au><au>Zaveta, Clara</au><au>Podewils, Felix</au><au>Möddel, Gabriel</au><au>Langenbruch, Lisa</au><au>Kovac, Stjepana</au><au>Mann, Catrin</au><au>Willems, Laurent M.</au><au>Schulz, Juliane</au><au>Fiedler, Barbara</au><au>Kurlemann, Gerhard</au><au>Schubert‐Bast, Susanne</au><au>Rosenow, Felix</au><au>Beuchat, Isabelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long‐term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow‐up</atitle><jtitle>Epilepsia (Copenhagen)</jtitle><addtitle>Epilepsia</addtitle><date>2021-12</date><risdate>2021</risdate><volume>62</volume><issue>12</issue><spage>2994</spage><epage>3004</epage><pages>2994-3004</pages><issn>0013-9580</issn><eissn>1528-1167</eissn><abstract>Objective
This study was undertaken to evaluate the long‐term efficacy, retention, and tolerability of add‐on brivaracetam (BRV) in clinical practice.
Methods
A multicenter, retrospective cohort study recruited all patients who initiated BRV between February and November 2016, with observation until February 2021.
Results
Long‐term data for 262 patients (mean age = 40 years, range = 5–81 years, 129 men) were analyzed, including 227 (87%) diagnosed with focal epilepsy, 19 (7%) with genetic generalized epilepsy, and 16 (6%) with other or unclassified epilepsy syndromes. Only 26 (10%) patients had never received levetiracetam (LEV), whereas 133 (50.8%) were switched from LEV. The length of BRV exposure ranged from 1 day to 5 years, with a median retention time of 1.6 years, resulting in a total BRV exposure time of 6829 months (569 years). The retention rate was 61.1% at 12 months, with a reported efficacy of 33.1% (79/239; 50% responder rate, 23 patients lost‐to‐follow‐up), including 10.9% reported as seizure‐free. The retention rate for the entire study period was 50.8%, and at last follow‐up, 133 patients were receiving BRV at a mean dose of 222 ± 104 mg (median = 200, range = 25–400), including 52 (39.1%) who exceeded the recommended upper dose of 200 mg. Fewer concomitant antiseizure medications and switching from LEV to BRV correlated with better short‐term responses, but no investigated parameters correlated with positive long‐term outcomes. BRV was discontinued in 63 (24%) patients due to insufficient efficacy, in 29 (11%) for psychobehavioral adverse events, in 25 (10%) for other adverse events, and in 24 (9%) for other reasons.
Significance
BRV showed a clinically useful 50% responder rate of 33% at 12 months and overall retention of >50%, despite 90% of included patients having previous LEV exposure. BRV was well tolerated; however, psychobehavioral adverse events occurred in one out of 10 patients. Although we identified short‐term response and retention predictors, we could not identify significant predictors for long‐term outcomes.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34608628</pmid><doi>10.1111/epi.17087</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-9745-7258</orcidid><orcidid>https://orcid.org/0000-0002-9300-4443</orcidid><orcidid>https://orcid.org/0000-0001-6288-9915</orcidid><orcidid>https://orcid.org/0000-0003-1545-7364</orcidid><orcidid>https://orcid.org/0000-0002-3989-7471</orcidid><orcidid>https://orcid.org/0000-0001-8226-1674</orcidid><orcidid>https://orcid.org/0000-0001-6663-2631</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0013-9580 |
ispartof | Epilepsia (Copenhagen), 2021-12, Vol.62 (12), p.2994-3004 |
issn | 0013-9580 1528-1167 |
language | eng |
recordid | cdi_proquest_miscellaneous_2579380324 |
source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Adolescent Adult Adverse events Aged Aged, 80 and over Anticonvulsants - adverse effects Child Child, Preschool Drug dosages Drug Therapy, Combination Epilepsy Epilepsy - chemically induced Epilepsy - drug therapy Etiracetam Female Follow-Up Studies Humans levetiracetam Levetiracetam - therapeutic use Male Middle Aged Patients Pyrrolidinones - adverse effects refractory Retention Retrospective Studies seizure Seizures SV2A Treatment Outcome Young Adult |
title | Long‐term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow‐up |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T00%3A28%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%E2%80%90term%20efficacy,%20tolerability,%20and%20retention%20of%20brivaracetam%20in%20epilepsy%20treatment:%20A%20longitudinal%20multicenter%20study%20with%20up%20to%205%C2%A0years%20of%20follow%E2%80%90up&rft.jtitle=Epilepsia%20(Copenhagen)&rft.au=Strzelczyk,%20Adam&rft.date=2021-12&rft.volume=62&rft.issue=12&rft.spage=2994&rft.epage=3004&rft.pages=2994-3004&rft.issn=0013-9580&rft.eissn=1528-1167&rft_id=info:doi/10.1111/epi.17087&rft_dat=%3Cproquest_cross%3E2579380324%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2604679380&rft_id=info:pmid/34608628&rfr_iscdi=true |